Advertisement

Other Malignancies

  • Michael von WolffEmail author
  • Martin F. Fey
Chapter
  • 14 Downloads

Abstract

In chapters “Breast Cancer, Hodgkin’s Lymphoma, Acute Leukaemia, Ovarian Tumours and Ovarian Cancer, Cervical Cancer, Endometrial Hyperplasia and Endometrial Carcinoma, Paediatric Oncological Cancer” and “Non-Malignant Diseases Requiring Stem Cell Transplantation; Severe Autoimmune Diseases; Endometriosis; Turner Syndrome; Transgender”, this book covers in detail approximately two-third of all diseases for which fertility preservation therapy is indicated. Other, but considerably less frequent diseases are presented in tabular form in this chapter in terms of their frequency, 5-year survival rate, gonadotoxicity of oncological treatment and the potential risk of gonadal metastases occurring. Recommendations for fertility preservation are derived from this. Overall, around 80% of the diseases requiring fertility preservation are described in this book.

Keywords

Anal cancer Cancer Ewing’s sarcoma FertiPROTEKT Glioma Liposarcoma Non-Hodgkin’s lymphoma Osteosarcoma Rectal cancer Testicular cancer 

References

  1. 1.
    Germeyer A, Dittrich R, Liebenthron J, Nawroth F, Sänger N, Suerdieck M, et al. FertiPROTEKT-Auswertungen 2018. J Reproduktionsmed Endokrinol. 2019;16:41–4.Google Scholar
  2. 2.
    Elis A, Tevet A, Yerushalmi R, Blickstein D, Bairy O, Dann EJ, et al. Fertility status among women treated for aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2006;47:623–7.CrossRefGoogle Scholar
  3. 3.
    Gini G, Annibali O, Lupasco D, Bocci C, Tomarchio V, Sampaolo M, et al. Gonadal function recovery and fertility in women treated with chemo- and/or radiotherapy for Hodgkin’s and Non-Hodgkin lymphoma. Chemotherapy. 2019;64:36–41.CrossRefGoogle Scholar
  4. 4.
    Briseño-Hernández AA, Quezada-López DR, Castañeda-Chávez A, Dassaejv Macías-Amezcua M, Pintor-Belmontes JC. Bilateral ovarian Burkitt’s lymphoma. A case presentation. Cir Cir. 2014;82:212–8.PubMedGoogle Scholar
  5. 5.
    Meirow D, Hardan I, Dor J, Fridman E, Elizur S, Ra’anani H, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod. 2008;23:1007–13.CrossRefGoogle Scholar
  6. 6.
    Hoekman EJ, Smit VT, Fleming TP, Louwe LA, Fleuren GJ, Hilders CG. Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach. Fertil Steril. 2015;103:469–77.CrossRefGoogle Scholar
  7. 7.
    Dolmans MM, Jadoul P, Gilliaux S, Amorim CA, Luyckx V, Squifflet J, et al. A review of 15 years of ovarian tissue bank activities. J Assist Reprod Genet. 2013;30:305–14.CrossRefGoogle Scholar
  8. 8.
    Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys. 2009;73:1304–12.CrossRefGoogle Scholar
  9. 9.
    Raciborska A, Bilska K, Filipp E, Drabko K, Rogowska E, Chaber R, et al. Ovarian function in female survivors after multimodal Ewing sarcoma therapy. Pediatr Blood Cancer. 2015;62:341–5.CrossRefGoogle Scholar
  10. 10.
    Greve T, Wielenga VT, Grauslund M, Sørensen N, Christiansen DB, Rosendahl M, et al. Ovarian tissue cryopreserved for fertility preservation from patients with Ewing or other sarcomas appear to have no tumour cell contamination. Eur J Cancer. 2013;49:1932–8.CrossRefGoogle Scholar
  11. 11.
    Abir R, Feinmesser M, Yaniv I, Fisch B, Cohen IJ, Ben-Haroush A, et al. Occasional involvement of the ovary in Ewing sarcoma. Hum Reprod. 2010;25:1708–12.CrossRefGoogle Scholar
  12. 12.
    Dolmans MM, Iwahara Y, Donnez J, Soares M, Vaerman JL, Amorim CA, Poirel H. Evaluation of minimal disseminated disease in cryopreserved ovarian tissue from bone and soft tissue sarcoma patients. Hum Reprod. 2016;31:2292–302.CrossRefGoogle Scholar
  13. 13.
    Sørensen SD, Greve T, Wielenga VT, Wallace WH, Andersen CY. Safety considerations for transplanting cryopreserved ovarian tissue to restore fertility in female patients who have recovered from Ewing’s sarcoma. Future Oncol. 2014;10:277–83.CrossRefGoogle Scholar
  14. 14.
    Longhi A, Pignotti E, Versari M, Asta S, Bacci G. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. Oncol Rep. 2003;10:151–5.PubMedGoogle Scholar
  15. 15.
    Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, Dearnaley DP. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005;93:200–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Gynaecological Endocrinology and Reproductive MedicineUniversity Women’s Hospital, University of BernBernSwitzerland
  2. 2.University Clinic for Medical Oncology, University of BernBernSwitzerland

Personalised recommendations